TY - JOUR
T1 - PD-L1 expression in neuroendocrine tumors of the lung
AU - Tsuruoka, Kenjiro
AU - Horinouchi, Hidehito
AU - Goto, Yasushi
AU - Kanda, Shintaro
AU - Fujiwara, Yutaka
AU - Nokihara, Hiroshi
AU - Yamamoto, Noboru
AU - Asakura, Keisuke
AU - Nakagawa, Kazuo
AU - Sakurai, Hiroyuki
AU - Watanabe, Shun ichi
AU - Tsuta, Koji
AU - Ohe, Yuichiro
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. Methods The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0–3] × stained area [0–100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Results Among the 227 patients included in this study, the patient demographics were as followsmedian age (range), 65 years (19–84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV)79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC)46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as followsTC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). Conclusions PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.
AB - Background Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung. Methods The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0–3] × stained area [0–100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression. Results Among the 227 patients included in this study, the patient demographics were as followsmedian age (range), 65 years (19–84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV)79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC)46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as followsTC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%). Conclusions PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.
KW - Carcinoid
KW - Clone E1L3N
KW - Immunohistochemistry
KW - LCNEC
KW - Neuroendocrine
KW - PD-1
KW - PD-L1
KW - Small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85016475713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016475713&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2017.03.006
DO - 10.1016/j.lungcan.2017.03.006
M3 - Article
C2 - 28625622
AN - SCOPUS:85016475713
SN - 0169-5002
VL - 108
SP - 115
EP - 120
JO - Lung Cancer
JF - Lung Cancer
ER -
